OmniSpirant
OmniSpirant Limited is a biotechnology company focused on developing innovative regenerative gene therapies for respiratory diseases and cancer. Their platform technology, OmniSomes, utilizes inhaled bioengineered stem cell exosomes for efficient intracellular delivery of RNA and protein therapeutics. The company aims to treat currently incurable lung diseases and various cancers through their advanced, first-in-class therapies, leveraging their patented inhaled exosome technology and strategic partnerships. They are committed to transforming medicine by creating therapies that are more effective, less toxic, and accessible.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Inhaled stem-cell-derived extracellular vesicle therapeutic platform
A platform of mucus-penetrating, stem-cell-derived extracellular vesicles engineered to deliver RNA and protein therapeutics to the lung (also assessed for systemic oncology delivery).
OS001
First-in-class regenerative gene therapy utilizing engineered stem cell exosomes developed for lung cancer and other types of cancer via systemic or targeted administration.
OS003
First-in-class regenerative gene therapy utilizing engineered stem cell exosomes developed for lung cancer and other types of cancer via systemic or targeted administration.
OmniSomes
A novel inhaled stem cell Extracellular Vesicle (exosome) based platform technology designed for pulmonary gene therapy and targeted delivery of genetic cargo to treat respiratory diseases.
Inhaled stem-cell-derived extracellular vesicle therapeutic platform
A platform of mucus-penetrating, stem-cell-derived extracellular vesicles engineered to deliver RNA and protein therapeutics to the lung (also assessed for systemic oncology delivery).
OS001
First-in-class regenerative gene therapy utilizing engineered stem cell exosomes developed for lung cancer and other types of cancer via systemic or targeted administration.
OS003
First-in-class regenerative gene therapy utilizing engineered stem cell exosomes developed for lung cancer and other types of cancer via systemic or targeted administration.
OmniSomes
A novel inhaled stem cell Extracellular Vesicle (exosome) based platform technology designed for pulmonary gene therapy and targeted delivery of genetic cargo to treat respiratory diseases.
Services
Collaborative development and co-development of RNA therapeutic assets leveraging EV manufacturing and pulmonary delivery expertise.
Collaborative development and co-development of RNA therapeutic assets leveraging EV manufacturing and pulmonary delivery expertise.
Expertise Areas
- Regenerative gene therapy
- Extracellular vesicle therapeutics
- Pulmonary drug delivery and aerosol science
- Preclinical respiratory disease modelling
Key Technologies
- Extracellular vesicles (exosomes) for therapeutic delivery
- Vibrating-mesh nebuliser aerosolisation
- Air-liquid interface cell culture models
- Small-animal aerosol administration models
News & Updates
OmniSpirant Therapeutics announced a US patent grant for its 'Extracellular Vesicles for Inhalation' technology with enhanced delivery properties, marking a significant milestone in their gene therapy platform development.
Galway, Ireland, 4th May 2023 - OmniSpirant announced the appointment of Andy Fisher, a leader with nearly 20 years of experience at United Therapeutics Corporation, to its board of directors.
Funding support from Emily's Entourage in the USA will help progress the development of OS001 for CF in collaboration with Queen's University Belfast.
OmniSpirant launched the INSPIRE project, a €12.8 million initiative funded by Horizon Europe, aiming to develop an inhaled gene therapy for lung cancer.
The company received a US patent for its extracellular vesicles for inhalation technology, enhancing delivery properties for gene therapy applications.
OmniSpirant received a US patent for its innovative extracellular vesicle platform for inhalation, supporting its therapeutic development.
OmniSpirant Therapeutics announced a US patent grant for its 'Extracellular Vesicles for Inhalation' technology with enhanced delivery properties, marking a significant milestone in their gene therapy platform development.
Galway, Ireland, 4th May 2023 - OmniSpirant announced the appointment of Andy Fisher, a leader with nearly 20 years of experience at United Therapeutics Corporation, to its board of directors.
Funding support from Emily's Entourage in the USA will help progress the development of OS001 for CF in collaboration with Queen's University Belfast.
OmniSpirant launched the INSPIRE project, a €12.8 million initiative funded by Horizon Europe, aiming to develop an inhaled gene therapy for lung cancer.
The company received a US patent for its extracellular vesicles for inhalation technology, enhancing delivery properties for gene therapy applications.
OmniSpirant received a US patent for its innovative extracellular vesicle platform for inhalation, supporting its therapeutic development.